NCT05423444

Brief Summary

Posttraumatic stress disorder in adolescence impairs neurobiological networks underlying cognitive, social and emotional skills. Neuroimaging research that seeks to identify the neural mechanisms of treatments for PTSD could lead to novel treatments, but progress has been slow using current methods. The proposed study uses an innovative approach to identify neural mechanisms of specific phases of trauma-focused therapy for youth with PTSD, allowing a new understanding of brain changes associated with the process of therapy.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
180

participants targeted

Target at P75+ for not_applicable

Timeline
10mo left

Started Nov 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress81%
Nov 2022Feb 2027

First Submitted

Initial submission to the registry

June 10, 2022

Completed
11 days until next milestone

First Posted

Study publicly available on registry

June 21, 2022

Completed
5 months until next milestone

Study Start

First participant enrolled

November 29, 2022

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2027

Last Updated

January 13, 2026

Status Verified

January 1, 2026

Enrollment Period

4.3 years

First QC Date

June 10, 2022

Last Update Submit

January 9, 2026

Conditions

Keywords

neuroimagingpsychotherapytraumaadolescent

Outcome Measures

Primary Outcomes (4)

  • Mean intensity within functional connectivity map of intrinsic network

    functional MRI scans will be used to assess neural connectivity

    week 0 (baseline)

  • Mean intensity within functional connectivity map of intrinsic network

    functional MRI scans will be used to assess neural connectivity

    week 6

  • Mean intensity within functional connectivity map of intrinsic network

    functional MRI scans will be used to assess neural connectivity

    week 12

  • Mean intensity within functional connectivity map of intrinsic network

    functional MRI scans will be used to assess neural connectivity

    week 18

Secondary Outcomes (1)

  • Clinician Administered PTSD Scale - children and adolescents (CAPS-CA)

    Baseline to week 18

Study Arms (2)

Trauma-focused cognitive behavioral therapy (TF-CBT)

EXPERIMENTAL

Trauma-focused Cognitive Behavioral Therapy (TF-CBT) is an evidence-based psychotherapy that is considered the gold-standard treatment for trauma in youth. The TF-CBT model is flexible but it follows a specific order of phases and components, including psychoeducation, emotion regulation skills, processing the trauma narrative, and safety planning. Sessions are provided weekly for 18-weeks.

Behavioral: TF-CBT

Treatment As Usual (TAU)

ACTIVE COMPARATOR

Treatment as usual (TAU) consists of the standard-of-care psychotherapy as provided by licensed clinicians at a local clinic. The order and choice of techniques is based on the knowledge and preferences of the clinicians. Sessions are provided weekly for 18-weeks.

Behavioral: TAU

Interventions

TF-CBTBEHAVIORAL

evidence-based psychotherapy for trauma in youth

Trauma-focused cognitive behavioral therapy (TF-CBT)
TAUBEHAVIORAL

treatment as usual

Treatment As Usual (TAU)

Eligibility Criteria

Age12 Years - 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • ages 12-17 and Tanner stage 2 or above
  • history of interpersonal trauma
  • PTSD symptoms with a rating of '2' or higher on at least one symptom from each of the 4 clusters, using the Clinician-Administered PTSD Scale for Children and Adolescents, and having a duration of at least one month

You may not qualify if:

  • current or past use of psychiatric medications
  • severe suicidal/homicidal ideation
  • current hospitalization
  • other current psychotherapy or previous treatment with TF-CBT
  • history of head injury with loss of consciousness for \>5 minutes
  • IQ\<85
  • major medical illness
  • MRI contraindications (metal in body; braces on teeth)
  • psychosis, bipolar 1, autism, developmental disorder, panic disorder
  • first-degree family member with diagnosis of psychosis or bipolar I disorder
  • substance dependence within the past 3 months or current drug use that is frequent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UT Health Department of Psychiatry

San Antonio, Texas, 78229, United States

RECRUITING

MeSH Terms

Conditions

Stress Disorders, Post-TraumaticPsychological TraumaWounds and Injuries

Condition Hierarchy (Ancestors)

Stress Disorders, TraumaticTrauma and Stressor Related DisordersMental Disorders

Study Officials

  • Amy Garrett, PhD

    The University of Texas Health Science Center at San Antonio

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Amy Garrett, PhD

CONTACT

Natalia Gomez-Giulilani

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
An independent assessor will conduct interviews to quantify symptom severity during and after treatment. The participant will not be given specific information about treatment assignment or the differences between the two treatments.
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: Randomized controlled trial of Trauma-focused Cognitive Behavioral Therapy (TF-CBT) versus Treatment as Usual (TAU)
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

June 10, 2022

First Posted

June 21, 2022

Study Start

November 29, 2022

Primary Completion (Estimated)

February 28, 2027

Study Completion (Estimated)

February 28, 2027

Last Updated

January 13, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will share

The data sharing plan and reporting of milestones will conform to all preferred NIMH guidelines, as detailed in the NDA Data sharing terms and conditions. Global unique identifiers (GUIDs) will be generated for each study subject. Data will be submitted to NDA every 6 months. We will provide a data submission agreement. The NDA validation tool will be used frequently. The clinical trial protocol also will be submitted as additional information for every collection. Progress reports will include a statement on the progress of data sharing. 1. Summary of data to be shared: neuroimaging, clinical, demographic, phenotypic, neuropsychological 2. Description of the data dictionaries used to describe the data set: Axis 1 diagnoses, CDI, CAPS-CA, fMRI behavior, beta weights, network correlations 3. Proposed schedule to validate that the data are compliant with the data dictionary: Data will be validated on a quarterly basis

Shared Documents
STUDY PROTOCOL
Time Frame
Immediately following publication. No end date.
Access Criteria
Researchers who provide a methodologically sound proposal
More information

Locations